Journal ArticleDOI
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
B Fisher,James J. Dignam,Norman Wolmark,D. Lawrence Wickerham,Edwin R. Fisher,Eleftherios P. Mamounas,Roy E. Smith,Mirsada Begovic,Nikolay V. Dimitrov,Richard G. Margolese,Carl G Kardinal,Maureen T. Kavanah,Louis Fehrenbacher,Robert H Oishi +13 more
TLDR
The combination of lumpectomy, radiation therapy, and tamoxifen was effective in the prevention of invasive cancer and the risk of ipsilateral-breast cancer was lower in the tamoxIFen group even when sample margins contained tumour and when DCIS was associated with comedonecrosis.About:
This article is published in The Lancet.The article was published on 1999-06-12. It has received 966 citations till now. The article focuses on the topics: Lumpectomy & Radiation therapy.read more
Citations
More filters
Journal ArticleDOI
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus,Stella Kyriakides,Frédérique Penault-Llorca,P.M. Poortmans,Alexander J. Thompson,Sophia Zackrisson,Fatima Cardoso +6 more
TL;DR: This work presents the results of a meta-analysis conducted at the 2016 European Oncology and Radiotherapy Guidelines Working Group (ESMO) workshop on breast cancer diagnosis and prognosis of women with atypical central giant cell granuloma (CGM) who have previously had surgery.
Journal ArticleDOI
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
Lyndsay Harris,Herbert A. Fritsche,Robert G. Mennel,Larry Norton,Peter M. Ravdin,Sheila E. Taube,Mark R. Somerfield,Daniel F. Hayes,Robert C. Bast +8 more
TL;DR: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and certain multiparameter gene expression assays not all applications for these markers were supported, however.
Journal ArticleDOI
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris,Herbert A. Fritsche,Robert G. Mennel,Larry Norton,Peter M. Ravdin,Sheila E. Taube,Mark R. Somerfield,Daniel F. Hayes,Robert C. Bast +8 more
TL;DR: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and not all applications for these markers were supported, however.
Journal ArticleDOI
Ductal Carcinoma in Situ of the Breast
TL;DR: Progress in the understanding, pathogenesis, and treatment of ductal carcinoma in situ is summarized.
Journal ArticleDOI
Side Effects of Adjuvant Treatment of Breast Cancer
Charles L. Shapiro,Abram Recht +1 more
TL;DR: Women with primary invasive breast cancer receive both local and systemic treatment to reduce the risk of recurrent cancer in the breast, chest wall, and regional lymph nodes.
References
More filters
Journal ArticleDOI
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
TL;DR: Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
Journal ArticleDOI
Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer
Bernard Fisher,M Bauer,Richard G. Margolese,Roger Poisson,Yosef Pilch,Carol K. Redmond,Edwin R. Fisher,Norman Wolmark,Melvin Deutsch,E Montague +9 more
TL;DR: It is concluded that segmental mastectomy, followed by breast irradiation in all patients and adjuvant chemotherapy in women with positive nodes, is appropriate therapy for Stage I and II breast tumors less than or equal to 4 cm, provided that margins of resected specimens are free of tumor.
Journal ArticleDOI
The analysis of failure times in the presence of competing risks.
Ross L. Prentice,John D. Kalbfleisch,A. V. Peterson,Nancy Flournoy,Vernon T. Farewell,Norman E. Breslow +5 more
TL;DR: It is argued that the problem of estimation of failure rates under the removal of certain causes is not well posed until a mechanism for cause removal is specified, and a method involving the estimation of parameters that relate time-dependent risk indicators for some causes to cause-specific hazard functions for other causes is proposed for the study of interrelations among failure types.
Journal ArticleDOI
A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
Bernard Fisher,Joseph P. Costantino,Carol K. Redmond,Roger Poisson,Bowman D,Couture J,Nikolay V. Dimitrov,Norman Wolmark,Wickerham Dl,Edwin R. Fisher +9 more
TL;DR: Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation and was attained with a low incidence of clinically appreciable toxic effects.
Journal ArticleDOI
Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer
Bernard Fisher,Joseph P. Costantino,Carol K. Redmond,Edwin R. Fisher,Richard G. Margolese,Nikolay V. Dimitrov,Norman Wolmark,Wickerham Dl,Melvin Deutsch,L Ore +9 more
TL;DR: Breast irradiation after lumpectomy is more appropriate than Lumpectomy alone for women with localized ductal carcinoma in situ, and five-year event-free survival was better in the women who received breast irradiation.